Defendant: Teva Pharmaceuticals USA, Inc. et al.; Granules USA, Inc.; Heritage Pharmaceuticals Inc. (d/b/a Avet Pharmaceuticals) | Category: Pharmaceutical & Medical Devices | Added: 2026-07-08
Alleged Issue
Generic metformin-containing drugs manufactured by the settling defendants were allegedly contaminated with the probable carcinogen NDMA and did not meet FDA standards, despite being marketed as equivalent to Glucophage/Glucophage XR.
Eligibility
Individuals or third-party payors who purchased, paid for, or reimbursed a metformin-containing drug made by Teva, Granules, or Heritage between July 20, 2015 and June 2, 2020, for personal or household use.
Estimated Payout
Pro-rata share of $5.55 million in combined settlement funds ($3M Teva + $2.55M Granules/Heritage). Economic-loss claims only, no personal injury.
Claim Deadline
2026-08-05
Background
The case actually resolves against three separate groups of defendants rather than one: Teva Pharmaceuticals USA and Teva Pharmaceutical Industries (along with related company Actavis) agreed to pay $3 million, while Granules USA and Granules Pharmaceuticals (along with related company Heritage/Avet) agreed to pay $2.55 million, for a combined settlement fund of about $5.55 million. All of the settling defendants deny they did anything wrong. Notably, the case is limited to economic-loss claims -- people who paid for the contaminated drug -- and does not cover any personal injury or wrongful death claims. The underlying litigation is still active against other, non-settling defendant manufacturers who did not join this settlement.